Generate Biomedicines Inc (GENB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$16.39+0.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GENB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -34.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 53.3% |
Growth built into the price is above our model estimate.
The price assumes 87.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
GENB — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Generate Biomedicines, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securi…
Why it matters: Results from this trial could impact the company's future in treating severe asthma. Positive results would support the drug's potential.
Watch forPositive results from the GB-0895 Phase 3 trial for severe asthma.
Also watch forNegative results from the GB-0895 Phase 3 trial.
Why it matters: Updates on the GB-0895 trials show how the program is doing. Strong recruitment may mean good interest and success.
Supportive ifRecruitment for SOLAIRIA-1 and SOLAIRIA-2 trials is going as planned.
Worry ifRecruitment is slowing down or facing big delays.
Why it matters: The data presentation could show the effectiveness of GB-0895 in COPD. Positive results may boost confidence in the drug's potential.
Supportive ifThe Phase 1b study had positive results. This was shared at the European Respiratory Society Congress on Sept. 8.
Worry ifThe results from the ERS Congress were negative or unclear.
Why it matters: Updates on cash runway will show funding needs and how long operations can last.
Worry ifManagement says they have enough cash to run operations until 2028.
Less concerning ifManagement says they need more money sooner than they thought.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$311 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $989 loss on $10,000 · 9.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,620 loss on $10,000 · 26.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Recruitment progress in the Phase 3 trials for GB-0895 is crucial for timely data collection. Delays could hinder the timeline.
Supportive ifRecruitment continues across all six global regions for the GB-0895 Phase 3 trials.
Worry ifRecruitment slows down a lot in any global region.
Why it matters: Monitoring cash burn is crucial as it impacts funding for ongoing trials. A high burn rate may signal funding needs.
Worry ifCash burn is steady with operations. It does not go over current projections.
Less concerning ifCash burn goes up a lot, which may mean funding problems.
Why it matters: Dosing the first patient in this trial signals progress in the oncology pipeline. This could indicate the company's ability to advance its programs.
Supportive ifFirst patient is dosed in the GB-5267 trial in the second half of 2026.
Worry ifDosing is delayed beyond the second half of 2026.
Why it matters: Advancing GB-0895 in severe asthma is crucial for the company's growth and pipeline strength.
Supportive ifManagement shares good news about GB-0895 Phase 3 trials.
Worry ifTrials face setbacks or delays.
Why it matters: If the sector's revenue growth slows, it could impact Generate Biomedicines. This could signal broader challenges in the healthcare sector.
Worry ifHealthcare sector revenue growth is now lower than its usual average.
Less concerning ifHealthcare sector revenue growth is still higher than its usual average.
Why it matters: The start of dosing could validate the MMAE neutralizer's development. It is a key step in the oncology pipeline.
Supportive ifFirst patient dosing for GB-4362 in the Phase 1 study occurs as planned in mid-2026.
Worry ifDosing is delayed beyond the expected timeline.
Why it matters: These studies are critical for GB-0895's approval in severe asthma. Progress could indicate strong market potential.
Supportive ifRecruitment is ongoing in all six global regions. This is for the SOLAIRIA-1 and SOLAIRIA-2 studies.
Worry ifThere are delays or problems in recruiting for the SOLAIRIA studies.
Why it matters: If revenue growth slows, it could signal a weakening position in a growing sector. This would concern investors about future performance.
Worry ifRevenue growth is below the sector's median. This may mean challenges ahead.
Less concerning ifRevenue growth is above the median. This shows the company is still performing well.